Alyeska Investment Group
INO icon

Alyeska Investment Group’s Inovio Pharmaceuticals INO Stock Holding History

Alyeska Investment Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,622
Closed -$657K – 490
2018
Q1 		$657K Sell
11,622
-105
-0.9% -$5.68K 0.01% 409
2017
Q4 		$581K Hold
11,727
– – ﹤0.01% 404
2017
Q3 		$892K Buy
+11,727
New +$873K 0.01% 420

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group's INO Position: Q2 2018 in Review

Alyeska Investment Group sold out of Inovio Pharmaceuticals (INO) in Q2 2018, closing a stake of 11,622 shares — an estimated $657K sold.

Alyeska Investment Group first reported a position in INO in Q3 2017 and held it in 3 quarters. The position peaked at $892K in Q3 2017. 126 funds tracked by Wall St. Rank hold INO as of Q2 2018.

  • Alyeska Investment Group reported no remaining Inovio Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 11,622 Inovio Pharmaceuticals shares in Q2 2018, an estimated $657K.
  • Alyeska Investment Group first reported a position in Inovio Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Alyeska Investment Group's Inovio Pharmaceuticals position peaked at $892K in Q3 2017.
  • 126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.